GT BIOPHARMA, INC. — Income Charts
46 quarters of history · ending 2021-09-30 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
Cost of Revenue
$0
Gross Profit
$0
R&D↑+1100.0% +$924K
$1M
SG&A↑+143.8% +$3M
$5M
D&A
$0
Operating Income↓-206.1% -$4M
$-6M
EBITDA↓-206.1% -$4M
$-6M
Interest Expense↓-100.0% -$931K
$0
Other Income/Expense↑+100.0% +$20M
$0
Pretax Income↑+90.4% +$27M
$-3M
Tax Provision
$0
Net Income↓-89.6% -$3M
$-5M
Gross Margin↑+68.0pts
100.0%
Operating Margin↓-6739.0pts
-7155.0%
Net Margin↑+135348.0pts
134300.0%
Effective Tax Rate↑+0.0pts
0.0%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+0.0pts
7.0%
Operating Lease Cost↓-99.9% -$17M
$15K
Revenue YoY Variation↓-80.0pts
-100.0%
Income YoY Variation↓-284.2pts
-206.1%
Revenue QoQ Variation↓-12.0pts
-100.0%
Income QoQ Variation↓-11.1pts
-35.9%